Modeling and Simulation of anakinra effects on severe COVID19 Patients.

We present here the results obtained by applying the Universal Immune System Simulator (UISS) computational platform in one declinations developed for COVID19 disease (UISS-COVID19) to model the efficacy, demonstrated during the SAVE-MORE study, of anakinra drug on patients affected by a severe illness induced by SARS-COV-2. The goal is to further validate the model capabilities and to confirm through computer simulations the biological hypotheses on the mechanisms of actions involved with the use of anakinra drug. UISS, and in silico models in general, have the potential to be integrated in future clinical trial pipelines and to be adopted as technologies to support clinical trials to evaluate the effectiveness of any drug or or xenobiotic.